Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects.
Bristol, 9th February 2022 - Bristol based, eXmoor Pharma is pleased to announce the appointment of Dr. Lucy Foley as Chief Technology Officer.
Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects. Her role will see her oversee the vector, analytics, cell therapy, and project verticals.
Lucy commented: “I’m thrilled to have joined eXmoor and to have the opportunity to work alongside Angela and the board. I am excited to be part of the growth journey eXmoor is on and its significant contribution to growing the UK as a world leader in cell and gene therapies.
Lucy joins eXmoor after eight years at the Centre for Process Innovation (CPI) with her most recent position as Director of Biologics and COVID response.
She recently led the establishment of the UK’s RNA Centre of excellence in response to the COVID-19 pandemic as a member of the UK Vaccines Taskforce. This established both PD and GMP facilities in the UK to provide resilience against future variants and pandemics by onshoring manufacturing and expertise.
In 2013, as the Lead Biopharmaceutical Engineer at CPI, Lucy collaborated with eXmoor on the concept design of the organisation’s Darlington-based National Biologics Manufacturing Centre.
Previously, she was an academic at Newcastle University in both the Business School and Chemical Engineering Departments where she worked with Professors Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies.
Lucy is already a familiar face to the eXmoor team as she serves as a founding leadership team member on the amc (ATMP Manufacturing Community) board alongside eXmoor CEO, Dr. Angela Osborne.
Angela Osborne commented: “I welcome Lucy to our growing team here at eXmoor. Her unprecedented industry experience will be integral to the next phase of our growth.”
Lucy holds a master’s degree in biochemical engineering with bioprocess management from University College London, and an engineering doctorate in biochemical engineering and bioprocess leadership from University College London.
Ends
About eXmoor
eXmoor has gone from strength to strength in the last few years and has experienced a fantastic period of fast growth. In 2017, eXmoor added process development laboratories to its consultancy base with world leading expertise in viral vector process development.
With a 40-strong staff team they have been involved in more than 400 contracts for over 125 organisations across the globe.
The company was founded in 2004 and has since grown into a globally recognised leader in its field that has completed more than 300 projects across 12 countries. The team works closely with clients to help them with commercialising a research process, developing fully licensed facilities, and providing QP services. eXmoor has won repeat business from nearly two thirds of all its clients since its launch.
eXmoor’s offices and process development laboratories are in Bristol, UK.
For further information please contact:
james.young@purplefish.agency, zoe.fawcett@purplefish.agency or joanna.randall@purplefish.agency
Tel: 0117 925 1358